Aerovate Therapeutics Stock Quote AVTE - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

1.90

Bid

1.90

Ask

1.94

Volume

0.00 Day's Range 0.00

1.25 52 Week Range 32.415

Market Cap

54.849M

Previous Close

1.90

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

377,606

Shares Outstanding

28,867,711

Dividend Yield

PE Ratio

-0.73

Earnings Per Share (EPS)

-2.62

Revenue

Net Profit

-75.52M

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hyper... Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.aerovatetx.com

Headquarters

Wilmington, Delaware, USA

Founded

Aerovate Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AVTE. The last closing price for Aerovate Therapeutics was $1.90. Over the last year, Aerovate Therapeutics shares have traded in a share price range of $ 1.25 to $ 32.415.

Aerovate Therapeutics currently has 28,867,711 shares outstanding. The market capitalization of Aerovate Therapeutics is $54.85 million. Aerovate Therapeutics has a price to earnings ratio (PE ratio) of -0.73.

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

WALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	1.9	2	1.875	273531	1.91744191	CS
4	0.03	1.60427807487	1.87	2	1.815	231021	1.90932536	CS
12	0.26	15.8536585366	1.64	2.08	1.57	377606	1.80885876	CS
26	-24.61	-92.8328932478	26.51	32.415	1.25	677818	4.85434827	CS
52	-11.45	-85.7677902622	13.35	32.415	1.25	382680	6.42906413	CS
156	-14.19	-88.1914232443	16.09	32.415	1.25	187062	10.16783688	CS
260	-26.1	-93.2142857143	28	32.415	1.25	183587	10.58910262	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NVVENuvve Holding Corporation	$ 7.16 (82.65%)	4.46M
SOXMTradr 2X Long SOXX Monthly ETF	$ 36.96 (58.98%)	57
NUKKNukkleus Inc	$ 0.3376 (58.87%)	19.8M
BDTXBlack Diamond Therapeutics Inc	$ 7.00 (47.06%)	4.62M
XPONExpion360 Inc	$ 0.1226 (44.58%)	12.42M
ZJYLJin Medical International Ltd	$ 3.18 (-22.06%)	43.98k
PRFXPainReform Ltd	$ 0.602 (-21.93%)	54.98k
AACGATA Creativity Global	$ 0.40 (-21.61%)	1
CJETChijet Motor Company Inc	$ 2.28 (-18.57%)	889
ADTXAditxt Inc	$ 0.3152 (-17.62%)	86.76k
NUKKNukkleus Inc	$ 0.3376 (58.87%)	19.8M
LGCBLinkage Global Inc	$ 0.5508 (31.68%)	12.96M
XPONExpion360 Inc	$ 0.1226 (44.58%)	12.42M
BDTXBlack Diamond Therapeutics Inc	$ 7.00 (47.06%)	4.62M
MAXNMaxeon Solar Technologies Ltd	$ 0.084 (-8.20%)	4.59M